Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

ADVM | Adverum Biotechnologies Inc

Index	-	P/E	-	EPS (ttm)	-1.33	Insider Own	12.61%	Shs Outstand	100.12M	Perf Week	-28.14%
Market Cap	121.19M	Forward P/E	-	EPS next Y	-1.00	Insider Trans	0.74%	Shs Float	88.26M	Perf Month	-32.58%
Income	-133.43M	PEG	-	EPS next Q	-0.32	Inst Own	56.27%	Short Float / Ratio	1.52% / 3.24	Perf Quarter	-22.08%
Sales	3.60M	P/S	33.66	EPS this Y	22.87%	Inst Trans	0.57%	Short Interest	1.34M	Perf Half Y	71.43%
Book/sh	1.30	P/B	0.92	EPS next Y	17.17%	ROA	-43.30%	Target Price	4.25	Perf Year	20.00%
Cash/sh	1.40	P/C	0.86	EPS next 5Y	-	ROE	-71.11%	52W Range	0.53 - 2.34	Perf YTD	107.08%
Dividend	-	P/FCF	-	EPS past 5Y	-3.90%	ROI	-67.76%	52W High	-48.72%	Beta	0.75
Dividend %	-	Quick Ratio	3.31	Sales past 5Y	-59.46%	Gross Margin	-276.72%	52W Low	125.99%	ATR	0.14
Employees	123	Current Ratio	3.31	Sales Q/Q	-	Oper. Margin	-3841.14%	RSI (14)	30.81	Volatility	11.10% 8.84%
Optionable	Yes	Debt/Eq	0.69	EPS Q/Q	29.25%	Profit Margin	-3706.47%	Rel Volume	0.31	Prev Close	1.19
Shortable	Yes	LT Debt/Eq	0.50	Earnings	Aug 10 AMC	Payout	-	Avg Volume	413.41K	Price	1.20
Recom	1.40	SMA20	-24.15%	SMA50	-30.48%	SMA200	3.89%	Volume	129,702	Change	0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-22	Upgrade	Truist	Hold → Buy	$4
Jul-23-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-03-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$5
Apr-29-21	Downgrade	Truist	Buy → Hold	$30 → $9
Apr-29-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$6
Apr-29-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$5
Dec-16-20	Initiated	UBS	Neutral	$13
Nov-12-20	Upgrade	Raymond James	Underperform → Mkt Perform
Jun-26-20	Downgrade	Raymond James	Mkt Perform → Underperform
May-13-20	Initiated	RBC Capital Mkts	Outperform	$24
May-05-20	Upgrade	SunTrust	Hold → Buy	$13 → $21
Apr-28-20	Initiated	Goldman	Buy	$17
Mar-16-20	Initiated	SVB Leerink	Outperform	$17
Feb-10-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$20
Feb-10-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$8 → $21
Oct-15-19	Reiterated	Chardan Capital Markets	Neutral	$6 → $10
Sep-13-19	Reiterated	Chardan Capital Markets	Neutral	$10 → $6
Jun-14-19	Resumed	Raymond James	Mkt Perform
Nov-02-18	Downgrade	SunTrust	Buy → Hold
Nov-02-18	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

Sep-26-23 04:05PM	Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial (GlobeNewswire) +7.50%
Sep-21-23 04:05PM	Adverum Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-05-23 04:05PM	Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-21-23 04:05PM	Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer (GlobeNewswire)
Aug-14-23 08:00AM	Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (GlobeNewswire) -5.29%
04:20PM	Loading…
Aug-10-23 04:20PM	Adverum Biotechnologies: Q2 Earnings Snapshot (AP Finance)
04:05PM	Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jun-12-23 08:00AM	Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid (GlobeNewswire)
Jun-02-23 08:00AM	Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference (GlobeNewswire) +6.14%
May-25-23 06:30AM	Adverum Biotechnologies Announces New Executive Leadership Roles (GlobeNewswire) +7.41%
May-18-23 09:00AM	Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vecs Phase 2 Clinical Development at ASGCT 2023 Annual Meeting (GlobeNewswire)
09:00AM	Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform (GlobeNewswire)
May-11-23 04:47PM	Adverum Biotechnologies: Q1 Earnings Snapshot (AP Finance)
04:05PM	Adverum Biotechnologies Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-10-23 04:05PM	Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +5.20%
04:30PM	Loading…
May-02-23 04:30PM	Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD (GlobeNewswire) -7.42%
Apr-23-23 01:00PM	Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec (GlobeNewswire)
Apr-21-23 06:03AM	After losing 12% in the past year, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners must be relieved by the recent gain (Simply Wall St.) -7.00%
Apr-18-23 08:00AM	Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD (GlobeNewswire)
Apr-17-23 04:05PM	Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting (GlobeNewswire)
Apr-04-23 09:40AM	Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-30-23 04:05PM	Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update (GlobeNewswire)
Mar-02-23 10:23AM	Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation (Simply Wall St.)
Feb-27-23 04:05PM	Adverum Biotechnologies to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-18-23 04:05PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-06-22 04:05PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-10-22 04:05PM	Adverum Biotechnologies Reports Third Quarter 2022 Financial Results (GlobeNewswire) +7.57%
Nov-04-22 12:08PM	Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022) (GlobeNewswire)
Oct-27-22 04:05PM	Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting (GlobeNewswire)
Sep-30-22 04:45PM	Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD (GlobeNewswire)
04:05PM	Loading…
Sep-27-22 04:05PM	Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-23-22 04:05PM	Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
11:06AM	Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation (Simply Wall St.)
08:00AM	Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022 (GlobeNewswire)
Sep-15-22 05:19PM	Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study (Zacks)
Sep-14-22 08:00AM	Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Sep-08-22 04:05PM	Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-26-22 04:05PM	Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase (GlobeNewswire)
Aug-11-22 04:05PM	Adverum Biotechnologies Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-10-22 04:05PM	Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference (GlobeNewswire)
Aug-01-22 04:05PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.48%
Jul-25-22 07:16AM	Quite a few insiders invested in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) last year which is positive news for shareholders (Simply Wall St.)
Jul-15-22 09:52AM	Adverum Posts New Data From Wet AMD Gene Therapy Trial (Benzinga) -5.71%
08:32AM	Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD (GlobeNewswire)
Jul-08-22 08:00AM	Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022 (GlobeNewswire) +9.29%
Jul-07-22 05:14PM	Gene therapy company cuts 78 jobs as it jump-starts program in blinding eye disease (American City Business Journals) +13.82%
11:22AM	Adverum (ADVM) Completes IND Amendment for Gene Therapy Study (Zacks)
08:02AM	Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022 (Benzinga)
Jul-06-22 04:05PM	Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMD (GlobeNewswire) +6.03%
09:31AM	Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? (PR Newswire)
Jun-24-22 08:00AM	Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD (GlobeNewswire)
Jun-09-22 08:00AM	Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD (GlobeNewswire)
Jun-02-22 04:05PM	Adverum Biotechnologies Announces New Data at the Macula Societys 2022 Annual Meeting (GlobeNewswire)
May-19-22 08:00AM	Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy (GlobeNewswire)
May-18-22 08:11AM	Adverum's Data at ASGCT Further Supports Phase 2 Development Plans For Wet-AMD Gene Therapy (Benzinga)
May-17-22 04:05PM	Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022 (GlobeNewswire)
May-12-22 04:05PM	Adverum Biotechnologies Reports First Quarter 2022 Financial Results (GlobeNewswire) -6.58%
May-11-22 02:51PM	How Much Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Do Institutions Own? (Simply Wall St.) -9.09%
May-09-22 04:05PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-22 04:30PM	Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022 (GlobeNewswire)
06:59AM	Adverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD (Benzinga)
May-01-22 02:15PM	Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting (GlobeNewswire)
Apr-19-22 06:00PM	Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022 (GlobeNewswire)
Apr-07-22 02:50PM	Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study (Zacks)
07:30AM	Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD (Benzinga)
Apr-06-22 04:05PM	Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA (GlobeNewswire)
Mar-29-22 04:05PM	Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-17-22 04:05PM	Adverum Appoints Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., to Board of Directors (GlobeNewswire) +6.30%
Mar-02-22 12:11PM	Should You Buy Adverum Biotechnologies (ADVM) Ahead of Earnings? (Zacks)
Feb-28-22 08:00AM	Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-15-22 04:22AM	Insiders who bought in the last 12 months lose an additional US$367k as Adverum Biotechnologies, Inc. (NASDAQ:ADVM) drops to US$136m (Simply Wall St.)
Feb-07-22 04:05PM	Adverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical Officer (GlobeNewswire)
Jan-06-22 04:05PM	Adverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development Officer (GlobeNewswire)
Jan-04-22 08:00AM	Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy (GlobeNewswire) -7.18%
Jan-01-22 06:02AM	Adverum Biotechnologies (NASDAQ:ADVM) investors are sitting on a loss of 84% if they invested a year ago (Simply Wall St.)
Dec-21-21 12:42PM	Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD (Benzinga)
08:00AM	Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022 (GlobeNewswire)
Dec-06-21 09:00AM	Adverum Biotechnologies Appoints Rupert DSouza, Ph.D., M.B.A. as Chief Financial Officer (GlobeNewswire)
Nov-30-21 10:25AM	Moore Kuehn, PLLC Encourages Investors of Adverum Biotechnologies, Inc. to Contact Law Firm (Newsfile) -6.95%
Nov-17-21 04:51AM	Here's What Adverum Biotechnologies, Inc.'s (NASDAQ:ADVM) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Nov-04-21 04:05PM	Adverum Reports Third Quarter 2021 Results (GlobeNewswire)
Oct-09-21 11:17AM	Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting (GlobeNewswire)
Oct-05-21 05:17AM	44 Biggest Movers From Yesterday (Benzinga) -10.00%
Oct-04-21 02:31PM	Mid-Afternoon Market Update: Dow Drops 375 Points; Elmira Savings Bank Shares Spike Higher (Benzinga) +10.09%
12:06PM	30 Stocks Moving In Monday's Mid-Day Session (Benzinga)
06:49AM	Adverum's Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, Safety (Benzinga)
Oct-03-21 08:14AM	Companies Like Adverum Biotechnologies (NASDAQ:ADVM) Are In A Position To Invest In Growth (Simply Wall St.)
Oct-01-21 04:00PM	Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections (GlobeNewswire)
Sep-27-21 09:00AM	Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences (GlobeNewswire) +6.28%
Aug-23-21 09:00AM	Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs (GlobeNewswire) +8.29%
Aug-19-21 07:05AM	Insiders might want to re-evaluate their US$613k stock purchase as Adverum Biotechnologies, Inc. (NASDAQ:ADVM) drops to US$217m (Simply Wall St.) -5.88%
Aug-06-21 10:19AM	Why Adverum Biotechnologies (ADVM) Might Surprise This Earnings Season (Zacks)
Aug-05-21 04:05PM	Adverum Reports Second Quarter 2021 Results (GlobeNewswire)
Jul-22-21 04:05PM	Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema (GlobeNewswire)
Jul-19-21 02:49PM	Hedge Funds Are Cashing Out Of Adverum Biotechnologies, Inc. (ADVM) (Insider Monkey)
Jul-01-21 08:00AM	Adverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs (GlobeNewswire)
Jun-28-21 12:00PM	Adverum Biotechnologies (ADVM) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jun-24-21 04:05PM	Adverum Announces Changes to Management Team (GlobeNewswire)
Jun-21-21 01:22AM	If You Had Bought Adverum Biotechnologies' (NASDAQ:ADVM) Shares A Year Ago You Would Be Down 85% (Simply Wall St.)
Jun-07-21 10:00AM	Why Adverum Biotechnologies Stock Sank in May (Motley Fool)

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Seyedkazemi Setareh	Chief Development Officer	Sep 15	Sale	1.52	6,201	9,429	47,674	Sep 18 06:54 PM
Rubinstein Linda M	Chief Financial Officer	Jun 07	Buy	1.45	100,000	145,490	100,000	Jun 09 04:26 PM
Fischer Laurent	CEO, President and Director	Mar 15	Sale	0.78	41,239	32,232	692,141	Mar 17 06:01 PM
Soparkar Peter	Chief Operating Officer	Mar 15	Sale	0.78	13,360	10,442	265,891	Mar 17 06:02 PM
Riley Brigit	Chief Scientific Officer	Mar 15	Sale	0.78	7,299	5,705	117,435	Mar 17 06:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADVM | Adverum Biotechnologies Inc

Upgrade your FINVIZ experience